This week, the health sector was on the eye of international stakeholders. On the one hand, the German Health Minister traveled to Mexico in search of health professionals who are interested in working in the country. Meanwhile, the pharmaceutical and biotechnology multinational Novartis warned about a halt in the distribution of a drug produced by its generic counterpart, Sandoz. The company is taking the necessary measures to solve a contamination issue and hopes the discovery brings hope and further innovations to the life in the health sector.
INTERVIEW OF THE WEEK
Mexico Health Review spoke with Katty Beltrán, Director General of Fundación Dibujando un Mañana, on how foundations can be an ally for companies’ efficient social investments.
- Novartis announced a halt in the distribution of medicines with ranitidine manufactured by Sandoz. This came as a preventive measure after discovering that the acid-reducing drugs were contaminated with NDMA, which is classified as a probable human carcinogen, according to laboratory tests by the FDA.
- Miguel Ángel Piza Jiménez was appointed Director General of the Health Institute of the State of Aguascalientes (ISSEA) and promised to implement a health policy that is sensitive to patients’ demands and that responds to financial and social challenges of the current society.
- German Health Minister Jens Spahn will be in Mexico today, looking to recruit more nurses to travel to Germany. For five years, the German government has been trying to attract not only academics but also those who practice non-academic professions from countries outside the EU to solve the shortage of specialized workers.
- The National Health Council (CONASA) will be in charge of communicating the list of medicines that will replace the so-called Basic Table. The list will be announced on December 4. The drug tender will be carried out to cover 62 percent of the medicines that were not covered in the first tender, which means that more than 1,900 products are currently waiting to be supplied.
- Lexmark announced the availability of four customized solutions designed to help healthcare companies in Mexico to increase efficiency, accuracy and continuity in results and improve communication between staff and patients.
- The Industrial Pharmacological Laboratory (LIF) developed misoprostol for gynecological use at affordable prices, unlike those sold in pharmacies in Argentina. The new medicine has already reached Santa Fe hospitals and health centers. Once ANMANT approves the initiative for other states, the drug will be available nationwide.
- Brazil has turned the alarms back on due to the proliferation of the Aedes aegypti mosquito. The country works against the clock to stop the progress of a new dengue outbreak, a disease that already accounts for about 1.5 million cases reported in 2019, the highest level since 2015.
Industry Analyst and Journalist at Mexico Business Publishing